Filing Details

Accession Number:
0001179110-14-002613
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-12 17:27:00
Reporting Period:
2014-02-11
Filing Date:
2014-02-12
Accepted Time:
2014-02-12 17:27:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1586105 Egalet Corp EGLT Pharmaceutical Preparations (2834) 463575334
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1591179 K/S Ii Fund Ventures Science Life Sunstone Lautrupsgade 7
5Th Floor
Copenhagen O G7 DK-2100
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-02-11 416,812 $0.00 416,812 No 4 C Direct
Common Stock Acquisiton 2014-02-11 736,826 $0.00 1,153,638 No 4 C Direct
Common Stock Acquisiton 2014-02-11 96,000 $0.00 1,249,638 No 4 X Direct
Common Stock Acquisiton 2014-02-11 202,658 $6.00 1,452,296 No 4 C Direct
Common Stock Acquisiton 2014-02-11 273,986 $6.00 1,726,282 No 4 C Direct
Common Stock Acquisiton 2014-02-11 133,333 $12.00 1,859,615 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 X Direct
No 4 C Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A-1 Preferred Stock Disposition 2014-02-11 416,812 $0.00 416,812 $0.00
Common Stock Series B Preferred Stock Disposition 2014-02-11 736,826 $0.00 736,826 $0.00
Common Stock Warrants Disposition 2014-02-11 96,000 $0.00 96,000 $0.00
Common Stock Subordinated Convertible Debt Disposition 2014-02-11 0 $0.00 202,658 $6.00
Common Stock Senior Convertible Debt Disposition 2014-02-11 0 $0.00 273,986 $6.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
0 No 4 X Direct
0 No 4 C Direct
0 No 4 C Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 154,938 Indirect By Egalet A/S
Footnotes
  1. The reporting person is Egalet A/S, a corporation. Sunstone Life Science Ventures Fund II K/S ("Sunstone") is a 12.0% equityholder of Egalet A/S.
  2. The Series A-1 Preferred Stock automatically converted into Egalet Corporation common stock on a 1-for-1 basis immediately prior to the consummation of Egalet Corporation's initial public offering.
  3. The Series B Preferred Stock automatically converted into Egalet Corporation common stock on a 1-for-1 basis immediately prior to the consummation of Egalet Corporation's initial public offering.
  4. The warrants were automatically exercised into Egalet Corporation common stock immediately prior to the consummation of the Egalet Corporation's initial public offering on a 1-for-1 basis, pursuant to Sunstone's purchase of a specified minimum amount of common stock in such offering.
  5. The subordinated convertible debt automatically converted into Egalet Corporation common stock immediately prior to the consummation of Egalet Corporation's initial public offering, based on a conversion price equal to 50% of the per share price in such offering, which was $12 per share.
  6. The senior convertible debt automatically converted into Egalet Corporation common stock immediately prior to the consummation of Egalet Corporation's initial public offering, based on a conversion price equal to 50% of the per share price in such offering, which was $12 per share.